SIGA Appoints Retired General John M. Keane to its Board of Directors

Core Viewpoint - SIGA Technologies, Inc. has appointed Retired United States Army General John "Jack" Keane to its Board of Directors, which is expected to enhance the company's strategic capabilities in national security and biodefense [1][4]. Company Overview - SIGA Technologies is a commercial-stage pharmaceutical company focused on developing innovative medicines to treat and prevent infectious diseases, particularly orthopoxviruses [5]. - The company's flagship product, TPOXX® (tecovirimat), is FDA-approved for the treatment of smallpox and authorized in several countries for related diseases [5]. Appointment of General Keane - General Keane brings 37 years of public service experience, including roles as acting Chief of Staff and Vice Chief of Staff of the U.S. Army, and is recognized as a national security expert [2][3]. - His insights into global security challenges are expected to be invaluable for SIGA as it aims to expand its antiviral reach and collaborate with government stakeholders [4]. Strategic Alignment - General Keane expressed his commitment to SIGA's mission, emphasizing the importance of preparedness in national security and the company's role in supplying TPOXX to the U.S. strategic national stockpile [4].